Lundbeck launches Sycrest in the UK for manic episodes of bipolar
This article was originally published in Scrip
Executive Summary
Lundbeck has launched its antipsychotic Sycrest (asenapine), for the treatment for moderate to severe manic episodes associated with bipolar I disorder in adults, in the UK.